Dosimetry Prediction for Clinical Translation of ⁶⁴Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.

ABSTRACT: The immune checkpoint programmed death 1 receptor (PD-1) expressed on some tumor-infiltrating lymphocytes, and its ligand (PD-L1) expressed on tumor cells, enable cancers to evade the immune system. Blocking PD-1 with the monoclonal antibody pembrolizumab is a promising immunotherapy strategy. Thus, noninvasively quantifying the presence of PD-1 expression in the tumor microenvironment prior to initiation of immune checkpoint blockade may identify the patients likely to respond to therapy. We have developed a ⁶⁴Cu-pembrolizumab radiotracer and evaluated human dosimetry. The tracer was utilized to image hPD-1 levels in two subcutaneous mouse models: (a) 293 T/hPD-1 cells xenografted into NOD-scid IL-2Rγnull mice (NSG/293 T/hPD-1) and (b) human peripheral blood mononuclear cells e

SUBMITTER: Natarajan A 

PROVIDER: S-EPMC5766550 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature